Delving into the Latest Updates on HP-011-101 with Synapse

Overview

Basic Info

Drug Type

Biological products

Synonyms

Xenaderm

Target

Trypsin

Action

stimulants

Mechanism

Trypsin stimulants

Therapeutic Areas

Skin and Musculoskeletal Diseases

Active Indication

Pressure Ulcer

Inactive Indication-

Originator Organization

Smith & Nephew plc

Active Organization

Smith & Nephew plc

Inactive Organization-

License Organization-

Drug Highest PhaseApproved

First Approval Date-

Regulation-

Login to view timeline

OBJECTIVETo discuss the clinical efficacy, indications, and application of Xenaderm in wound care management.DATA SOURCESHealthcare literature from Medline and Ovid databases that focus on clinical trials and case studies that used Xenaderm to evaluate duration of wound healing.STUDY SELECTIONInclusion criteria for article selection: (1) articles on clinical trials and case studies in which Xenaderm was the focus of the wound therapy, (2) articles written in English, and (3) articles published later than 2003. Studies that did not meet the inclusion criteria were excluded.CONCLUSIONOutcomes from clinical trials demonstrate that Xenaderm is efficacious and successful in healing wounds twice as fast as saline-treated wounds. Use of Xenaderm is considered safe and cost-effective. Xenaderm is eligible to be included in the wound care management algorithm and is recommended to be used on most partial-thickness wounds. Results from clinical trials show that Xenaderm is an essential topical therapy to facilitate wound healing, decrease hospital financial costs, and improve the quality of life for patients who acquire iatrogenic skin damage.

01 Jan 2004·Journal of Wound, Ostomy and Continence NursingQ3 · MEDICINE

A Shared Goal for Wound and Continence Care

Q3 · MEDICINE

Review

Author: Gray, Mikel

Perineal dermatitis is frequently encountered in patients with urinary and/or fecal incontinence, particularly when managed by a containment device such as a pad or containment brief. In addition to intervening to prevent or alleviate incontinence, a preventive perineal skin program in the high-risk patient and aggressive management of incontinence-related dermatitis are both essential for effective holistic management. A routine cleansing regimen that removes irritants and moisturizes while protecting the skin from additional irritation is effective for prevention of dermatitis and for managing mild cases. However, more aggressive care is required when perineal dermatitis occurs, especially when it is associated with epidermal erosion. Xenaderm ointment combines three active ingredients in a hydrophobic ointment that promotes healing while acting as a moisture barrier to prevent further irritation and damage.

100 Deals associated with HP-011-101

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	D03	-

R&D Status

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Pressure Ulcer	-	Smith & Nephew plc	-

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01433159 (CTgov)	Phase 2	Spinal Cord Injuries \| Pressure Ulcer	19	HP011-101 (Xenaderm Ointment)	tpaqvwuviu(ihyuymkygj) = trribfrqah aplbajawoj (ourcpgsdcc, gvzzdvcnin - pxzorrqmhu) View more	-	10 Feb 2014
NCT00645164 (CTgov)	Phase 1	-	59	Ointment Vehicle+Xenaderm	rldssmnmxl(bvtlbzkpys) = xboqjzsvyf uceovpvwip (dzelzagbpe, yvbaopoujn - crftoucqqv) View more	-	06 Apr 2009